BRCA2 and breast carcinoma: For example, application of the NCCN version 2.2017 criteria to a cohort of 1371 newly diagnosed breast cancer patients from Norway who were tested for BRCA1 and BRCA2 mutations, revealed that 32 of 38 (88.9%) mutation carriers would have been classified as high-risk [13].